Sign In
Buy AMRX
$12.88
+0.225 (+1.78%)
At Close: Jun 03, 2026
Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico
07:30am, Tuesday, 05'th Aug 2025
MONTREAL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo
Amneal Reports Second Quarter 2025 Financial Results
06:00am, Tuesday, 05'th Aug 2025
‒ Q2 2025 Net Revenue of $725 million ; GAAP Net Income of $22 million ; Diluted Income per Share of $0.07 ‒ ‒ Adjusted EBITDA of $184 million ; Adjusted Diluted EPS of $0.25 ‒ ‒ Raising 202
Amneal (AMRX) is an Incredible Growth Stock: 3 Reasons Why
01:46pm, Tuesday, 29'th Jul 2025
Amneal (AMRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?
11:05am, Tuesday, 29'th Jul 2025
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Think Amneal (AMRX) Could Surge 43.82%: Read This Before Placing a Bet
10:56am, Tuesday, 29'th Jul 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 43.8% in Amneal (AMRX). While the effectiveness of this highly sought-after metric is questionable, the positiv
Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year?
10:41am, Monday, 28'th Jul 2025
Here is how Amneal Pharmaceuticals (AMRX) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032
07:39am, Monday, 21'st Jul 2025
BRIDGEWATER, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal”) (Nasdaq: AMRX) announced that its subsidiary, Amneal Pharmaceuticals LLC (the “Issuer”), is seeking
Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results
07:38am, Monday, 21'st Jul 2025
– Results Reflect Continued Financial Strength and Deleveraging – BRIDGEWATER, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company�
MONTREAL, July 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that Knight's New Drug Submission
Amneal to Report Second Quarter 2025 Results on August 5, 2025
08:00am, Wednesday, 09'th Jul 2025
BRIDGEWATER, N.J., July 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Compa
Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year?
10:40am, Monday, 30'th Jun 2025
Here is how Amneal Pharmaceuticals (AMRX) and AtriCure (ATRC) have performed compared to their sector so far this year.
Amneal holds exclusive U.S. commercialization rights; BLA filing expected in Q4 2025 Poised to be among the first wave of biosimilars in the $3.9 billion U.S. omalizumab market and an important growth
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?
10:46am, Friday, 13'th Jun 2025
Here is how Amneal Pharmaceuticals (AMRX) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
08:00am, Thursday, 12'th Jun 2025
BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of prednisolo
Wall Street Analysts Believe Amneal (AMRX) Could Rally 54.36%: Here's is How to Trade
11:01am, Wednesday, 04'th Jun 2025
The consensus price target hints at a 54.4% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r
